Key Takeaways
- Inflection point reached, profitability to resume: Management declared the company is at an inflection point after years of heavy CAPEX, with France ready, the co-investment project commercializing, and a confident call for a return to positive profit territory in the current fiscal year.
- Q4 margin hit from one-off cost spikes: EBITDA margin was pressured by a COGS spike to ~29% of revenue in Q4, driven by a mix shift to higher-material-cost commercial supplies and raw material inflation on cholesterol and Vitamin D analogues.
- Regulatory clearance is the near-term catalyst: EDQM inspection is expected between now and December, and PMDA audit is confirmed for early August; key customers are already placing orders ahead of formal clearance, signaling confidence in a positive outcome.
- Ambitious medium-term targets set: Management is eyeing a return to 25–26% EBITDA margin in '25, '26 and at least a 12–15% revenue CAGR over the next 5 years, underpinned by operational excellence and new asset utilization.
- What to watch next quarter: The outcome of the PMDA audit in August, any EDQM inspection announcement, and whether the Q4 cost spike reverses as the revenue mix normalizes.
The Inflection Point: CAPEX Cycle Ends, Commercialization Begins
- Multi-year CAPEX program largely complete: The new injectables plant in France was inaugurated in February 2023, the Swiss co-investment expansion is under qualification, and major India upgrades (new QC lab, warehouse, effluent treatment) are finished. Most CAPEX outside India is now complete except for maintenance and the SAP implementation across Carbogen Amcis.
- France is the next growth engine: The French facility enables development and manufacturing of injectables at a larger scale, with management citing a very strong pipeline of new projects and huge appetite from new customers to use the unit.
- Swiss co-investment project entering revenue phase: The expansion is complete, the product is already on the Japanese market, and the first pre-commercial validation campaign is underway; management is confident of generating some revenue in FY24.
- Bavla poised for full production: With the EDQM overhang likely to be resolved completely, the site should see near-full production across all 8 or 9 units, driving a step-up in India revenue and group operating profitability.
- One greenfield project shelved: The Hunzenschwil project in Switzerland was impaired (₹45.6 crores) and put on hold to prioritize the French plant and ADC expansion, and to avoid taking on too much additional debt; management is assessing whether the design costs can be repurposed for other CAPEX projects.
Sanjay Majmudar: "I think we are at the inflection point, almost everything that should have been corrected has been put in place. France is ready to go. The co-investment project will be commercialized."
Regulatory Catalysts: EDQM and PMDA
- EDQM inspection expected in H2 CY23: Regulators invited in October last year have come back with additional queries; management makes a "calculated assumption" that the inspection can be expected any time between now and December.
- PMDA audit confirmed for early August: The Japanese Regulatory Authority is scheduled to audit from 1st to 4th August; management views this as an administrative milestone given the Swiss site's history of successful audits by U.S. and other authorities, but the audit will occur after the first validation campaign.
- Customers are pre-ordering: Key customers, impressed by audits and facilities, have decided to take a risk and start ordering ahead of regulatory clearance, a tangible signal of confidence in a positive outcome.
- Established regulatory relationships de-risk the process: PMDA and EMA have been working closely with 50-plus other regulators; management believes this established relationship, along with successful customer audits, supports a positive EDQM outcome.
Arpit Vyas: "They have been extremely impressed and many of them have decided to take a risk and start ordering looking at the facilities and the quality of the talent that has been seen during the audit."
Q4 FY23 Margin Dissection: One-Off Cost Spikes
- COGS spike to ~29% of revenue: Q4 COGS was abnormally high versus the ~20–21% full-year average because of two factors: more commercial supplies at Carbogen Amcis Switzerland, where material costs are higher than development projects, and higher raw material costs for cholesterol and Vitamin D analogues at the Dutch facility, combined with higher cholesterol sales in the quarter.
- Full-year EBITDA margin declined to 17.2%: The ~100 bps drop from 18.2% in FY22 was partly driven by a ₹18.5 crore increase in energy costs across at least 5 European manufacturing sites.
- Other expenses surged 40% YoY: Full-year other expenses rose to ₹534 crores, mostly from translation impact of USD and Swiss franc into INR, including ~₹50 crores of mark-to-market FOREX loss.
- FOREX loss was a double translation whammy: In Switzerland, customer payments received in USD are converted to CHF at cut-off dates, creating a mark-to-market loss in the Swiss P&L; then CHF is converted to INR for consolidated reporting, amplifying the impact even though there is no underlying risk.
- Finance costs rose on global rate hikes: Higher USD and Swiss franc LIBOR rates increased finance costs in Q4 and the full year.
- One-time expenses added pressure: Q4 included R&D expenses for own projects (especially the Vitamin D collaboration with Boston University) and nonrecurring consultancy expenses of about ₹4.2 crores.
- Onerous contracts provision of ₹42 crores: Under conservatism, when estimated total man-hours on development projects exceed budgeted hours, the incremental cost is expensed; provisions are reversed later if the extra hours are not incurred or if the customer agrees to pay.
- SaaS IT costs of ₹10 crores expensed: Relates to Microsoft D365 implementation in France, which under IFRIC interpretation must be expensed rather than capitalized; the implementation is complete and no major costs are expected going forward.
Operational Excellence: Site-by-Site Progress
- Naroda delivered an excellent year: Revenue growth was strong, several customer audits were passed, and a culture of continuous improvement is taking hold; new highly sophisticated equipment is being added and processes are being clubbed together to achieve better margins going forward.
- Bavla transformation is materializing: The site saw big progress in redesign, including one of the best warehouses in the industry, a new automated QC lab from a German supplier that doubles QC capacity, and major improvements in waste treatment and water treatment.
- Bavla revenue seasonality is pronounced: Q4 revenue is historically much higher than Q3 because most revenue comes from exports and customers avoid shipments post 15 December due to Christmas.
- Swiss site is audit-ready: The site has been visited many times by different authorities; the co-investment expansion is complete and under qualification, with orders already in hand and the first pre-commercial validation campaign underway.
- New stability chambers and purified water plant: A brand-new stability chamber facility with top-of-the-line temperature and humidity control is complete; a purified water plant from Swiss company BWT, the largest capacity plant BWT has installed in India, is under construction and expected to be completed within the year.
Arpit Vyas: "I have seen quite a few warehouses across the globe. And trust me when I say that what has been created is truly something unseen at least in our industry."
Balance Sheet and Capital Allocation
- Debt peaked on front-ended CAPEX: Gross debt rose primarily because CAPEX projects were front-ended and needed to be finished quickly; approximately 60% of the ~₹400 crore net debt increase was pure currency translation.
- Management prefers debt as a permanent tool: The company likes to use debt as a financial tool rather than deploy its own cash flows, and intends to keep debt on its books even as net debt reduces going forward; an analyst's suggestion to prioritize deleveraging was acknowledged but not adopted.
- Free cash flow was negative but expected to turn: FCF was negative because CAPEX was front-ended; management does not expect FCF to remain negative going forward.
- Asset turn guidance of ~1x: On the ~₹1,800 crores of CAPEX done post-FY19, management estimates peak revenue potential at ~₹3,800 crore, implying an asset turn of roughly 1x.
- Next major CAPEX cycle is distant: No major CAPEX programs are planned; the next round of large CAPEX should only happen once the company reaches peak revenue levels. Maintenance plus growth CAPEX going forward is pegged at roughly EUR 40 million per year.
- Related-party loan being repaid: Part of the related-party loan balance (~₹19 crores) was repaid post 31 March, and the plan is to clear the remainder before the end of FY24.
Arpit Vyas: "In our business, as a company, we like to use debt as a financial tool rather than use our own cash flows that we would like to invest."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Return to positive profit territory | Confident of coming into positive profit territory in the current fiscal year | FY24 |
| EBITDA margin recovery | Move back to 25–26% EBITDA margin (achieved in FY19–20) | FY25–26 |
| Revenue CAGR | At least 12–15% CAGR over the next 5 years | 5-year horizon |
| Bavla full production | Near-full production of all 8 or 9 units, with revenue much higher than FY23 | FY24 |
| EDQM inspection | Expected any time between now and December, per management's calculated assumption | H2 CY23 |
| PMDA audit | Confirmed for 1st to 4th August | August 2023 |
| French facility operations | Final qualification grant about to start; operations expected to begin | FY24 |
| Swiss co-investment revenue | Confident of generating some revenue | FY24 |
| CAPEX run rate | CHF 3.5–4 crore consolidated | FY24 |
| Maintenance + growth CAPEX | Roughly EUR 40 million a fair figure going forward | Ongoing |
| Free cash flow | Not expected to remain negative | Going forward |
| Related-party loan repayment | Plan to clear before completion of the fiscal year | FY24 |
| SAP/HANA ERP implementation | Target to implement new ERP | Q1 FY24 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Net revenue | ₹618.6 cr, compared to ₹569 cr in Q4 FY22 |
| Full-year FY23 revenue | ₹2,413 cr, growth of almost 12% over FY22 |
| Adjusted EBITDA | ₹83 cr, compared to ₹77 cr in Q4 FY22; adjusted for mark-to-market FOREX losses, SaaS IT costs, and nonrecurring expenses |
| Full-year FY23 adjusted EBITDA | ₹414 cr, compared to ₹390 cr in FY22 |
| Full-year FY23 adjusted EBITDA margin | 17.2%, compared to 18.2% in FY22; energy costs increased by almost ₹18.5 cr |
| Reported EBITDA | ₹51 cr, compared to ₹22 cr in Q4 FY22 |
| COGS as a percentage of revenue | 29% for Q4 FY23, higher than the full-year average of roughly 20% to 21% due to commercial supplies mix and higher cholesterol raw material costs |
| Other expenses | ₹132 cr, a decline of about 10% from ₹147 cr in Q4 FY22; includes mark-to-market FOREX loss of about ₹16.5 cr |
| Full-year mark-to-market FOREX loss | ₹50 cr |
| Exceptional items | ₹45.6 cr (about CHF 0.54 cr), impairment of design and engineering costs for a greenfield project put on hold |
| Full-year additional provision for onerous contracts | ₹42 cr net addition, outstanding provision as of March 31, 2023 roughly ₹55 cr |
| One-time R&D and consultancy expenses | ₹4.2 cr, for Vitamin D project with Boston University and nonrecurring consultancy |
| Net debt (excluding liabilities) | CHF 15.9 cr as of March 31, 2023 |
| Full-year capital expenditure | $69 million |
| Carbogen Amcis total turnover (FY23) | CHF 24.4 cr, 12% increase on target |
| Gross debt | ₹1,800 cr, 80% to 90% denominated in Swiss francs; interest cost roughly 4% to 4.5% on average |
| Bavla Q4 revenue run-rate | ₹70 cr |